GEN Exclusives

More »

GEN News Highlights

More »
May 14, 2013

Study Points to Potential Biomarker for Atherosclerosis

  • In the search for early biomarkers for atherosclerosis, researchers at the Montreal Heart Institute have found that a particular protein, angiopoietin-like 2 (angptl2), promotes atherogenesis in mice.

    They also found that blood levels of angptl2 to be six times higher in patients with coronary heart disease than healthy people of the same age.

    "Prevention is the ideal solution to delay the onset of atherosclerosis, and an early blood marker such as angptl2—if future clinical studies confirm this finding—will serve as an important tool to identify at-risk subjects who do not present with any symptoms of atherosclerotic disease,” Montreal Heart Institute’s Éric Thorin, Ph.D., said in a statement.

    Thorin and his colleagues also found that angptl2, which is undetectable in young mice, increases with age in healthy animals, and prematurely so in those with high cholesterol and pre-atherosclerotic lesions.

    "Although much work remains to be done to broaden our knowledge of this protein's mechanisms of action, angiopoietin-like protein 2 may represent an early biomarker not only to prevent vascular damage but also to predict atherosclerotic disease," Dr. Thorin added.

    The study “Angiopoietin-like 2 promotes atherogenesis in mice” appeared online in the Journal of the American Heart Association on May 10.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »